Author

Hilde Carlier

IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CROHN’S DISEASE: A PHASE 2 STUDY ANALYSIS USING THE SF-36
IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CROHN’S DISEASE: A PHASE 2 STUDY ANALYSIS USING THE SF-36

Hilde Carlier  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHN’S DISEASE: 104-WEEK EXTENSION RESULTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL
EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHN’S DISEASE: 104-WEEK EXTENSION RESULTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL

Hilde Carlier  et al.

ASSOCIATION OF HISTOLOGIC-ENDOSCOPIC RESPONSE AND LONG-TERM CLINICAL OUTCOMES: RESULTS FROM PHASE 2 MIRIKIZUMAB TRIAL IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN’S DISEASE
ASSOCIATION OF HISTOLOGIC-ENDOSCOPIC RESPONSE AND LONG-TERM CLINICAL OUTCOMES: RESULTS FROM PHASE 2 MIRIKIZUMAB TRIAL IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN’S DISEASE

Hilde Carlier  et al.

IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH CLINICAL REMISSION AND PAIN IMPROVEMENTS BUT NOT WITH ENDOSCOPIC RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH CLINICAL REMISSION AND PAIN IMPROVEMENTS BUT NOT WITH ENDOSCOPIC RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Hilde Carlier  et al.

IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Hilde Carlier  et al.

Item 1 - 5 / 5
1